NCT03923842UNKNOWNanonymous

Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study

Sponsor

Source record

Gruppo Oncologico del Nord-Ovest

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Indication / condition

AI-normalized

Nasopharyngeal Carcinoma

Intervention

Source record

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Source & freshness

Source record

NCT ID

NCT03923842

Original source

ClinicalTrials.gov

Source last updated

Feb 17, 2020

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03923842

Title

Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study

Sponsor

Gruppo Oncologico del Nord-Ovest

Status

UNKNOWN

Phase

PHASE2

Condition raw

Nasopharyngeal Carcinoma, EBV Related Carcinoma

Condition normalized

Nasopharyngeal Carcinoma, EBV Related Carcinoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Target normalized

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Interventions

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Public preview

Source record

The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab In Ebv Related Nasopharyngeal Carcinoma (Npc) As A Model For Rank-Mediated Immunologic Modulation Of Virus-Related Tumours - Dern Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03923842

Status

UNKNOWN

Phase

PHASE2

Sponsor

Gruppo Oncologico del Nord-Ovest

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 17, 2020

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03923842

Indication

Nasopharyngeal Carcinoma

Modality

small molecule

Target

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Intervention

Denosumab Inj 120 MG/1.7ML, Chemotherapy as clinical standard of care

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.